Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portf...
Q1 2026
Apr 27, 2026
FY 2025
Apr 24, 2026
Q3 2025
Dec 22, 2025
Q1 2025
Apr 3, 2025
FY 2024